Literature DB >> 1801857

Combined hemodialysis-hemoperfusion in the treatment of secondary hyperparathyroidism of uremic patients.

P Morachiello1, S Landini, A Fracasso, F Righetto, F Scanferla, P Toffoletto, R Genchi, G Bazzato.   

Abstract

Hyperparathyroidism and its related symptoms such as bone pain, soft-tissue calcifications and pruritus often get worse during dialysis treatment. We have treated 12 cases among 170 patients on regular dialysis by using coated charcoal (150 g/cartridge) in combination with standard hemodialysis. During a 6-month treatment period, without changing medical therapy and diet regime, the patients reported a marked relief from pruritus. Parathyroid hormone (PTH) levels changed from 552 +/- 86 to 364 +/- 62 pg/ml (p less than 0.001) compared to the pretreatment period, Plasma PO4(3-) changed in the same period from 6.9 +/- 1.8 to 4.6 +/- 1.5 mg/dl (p less than 0.005). The results obtained indicate a relationship between PTH, serum plasma PO4(3-) levels and pruritus. The mechanism which may be involved is that hemoperfusion removes PTH excess by absorption. Our treatment reducing PTH levels resulted in a marked relief from pruritus and other symptoms, suggesting that patients in this condition, before undergoing surgical parathyroidectomy, may be usefully treated with this therapeutic modality.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1801857     DOI: 10.1159/000170011

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  3 in total

Review 1.  Uremic Pruritus: From Diagnosis to Treatment.

Authors:  An-Yu Cheng; Lai-San Wong
Journal:  Diagnostics (Basel)       Date:  2022-04-28

2.  Role of narrow band ultra violet radiation as an add-on therapy in peritoneal dialysis patients with refractory uremic pruritus.

Authors:  Ranjeeta Sapam; Rajesh Waikhom
Journal:  World J Nephrol       Date:  2018-08-07

Review 3.  Hemoperfusion: technical aspects and state of the art.

Authors:  Claudio Ronco; Rinaldo Bellomo
Journal:  Crit Care       Date:  2022-05-12       Impact factor: 19.334

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.